NCT01365468View on ClinicalTrials.gov

Efficacy and Safety of RAD001 in Treating Plexiform Neurofibromas (PN) Associated With Neurofibromatosis (NF1)

PHASE2TerminatedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions
Plexiform Neurofibroma Associated With Neurofibromatosis Type 1
Interventions
DRUG

Everolimus (RAD001)

oral daily dosing of tablet starting with 2.5 mg

Trial Locations (2)

52621

Novartis Investigative Site, Tel Litwinsky

6423906

Novartis Investigative Site, Tel Aviv

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY